Roka Bioscience (ROKA) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Roka Bioscience Reports Second Quarter 2015 Financial Results
August 13, 2015 4:01 PM EDTWARREN, N.J., Aug. 13, 2015 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the quarter and six months ended June 30, 2015.
Second Quarter Financial Results:Â
Revenue for the quarter ended June 30, 2015 was $1.5 million compared with $1.4 million for the second quarter of 2014 and $1.5 million for the first quarter of 2015. As of June 30, 2015, the Company had 41 instruments placed with customers under commercial agreements compared to 36 instruments as of June 30, 2014 and 41 instruments as of... More
